期刊
POSTGRADUATE MEDICINE
卷 123, 期 1, 页码 34-44出版社
TAYLOR & FRANCIS LTD
DOI: 10.3810/pgm.2011.01.2243
关键词
obesity; metabolic syndrome; pharmacological management; comorbidity; diabetes
资金
- Welcome Trust
- Integrative Mammalian Biology (IMB) Capacity Building Award [FP7-HEALTH-2009-241592]
- NIHR Biomedical Research Centre
- Medical Research Council [G7811974] Funding Source: researchfish
- MRC [G7811974] Funding Source: UKRI
Obesity is a pandemic with many complications that increase the societal disease burden and cost of health care, and decrease longevity and quality of life. Currently, 1 in 3 adults in the United States is obese. Physicians must therefore regularly confront obesity and its consequent diseases, and develop strategies for effective treatment and management. This article summarizes current lifestyle modifications, pharmacological treatment, and surgical options for the management of obesity and discusses the benefits, limitations, and risks of each. As insights are gained into the pathophysiology of a gut-brain neurochemical feedback axis governing satiety and feeding behavior, targets for new pharmacotherapies are being developed. In particular, gut hormone analogs are an attractive antiobesity therapy because they appear to lack the adverse effects historically associated with central nervous system-acting agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据